Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (294 reviews)

For research use only. Not for use in humans.

Catalog No.S1065 Synonyms: RG7321

294 publications

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 294 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )
Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )
Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )
Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )
PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )
Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )
Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )
Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MlzGT4lv[XOnIFHzd4F6		NEX5V3EyKGh?	NX7W[G9FTE2VTx?=	MmS2TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh\|ryP	NGm4coQyQDd3NE[1OC=>
Sf9	MXTLbY5ie2ViQYPzZZk>		NHTyR5gyKGh?	NV7kTYNvTE2VTx?=	NYD1fFIxUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEhzMES3MXIhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	M{PLSFE5PzV2NkW0
Sf9	NFe3PXVMcW6jc3WgRZN{[Xl?		NXKxbYxyOSCq	M4TMVGROW09?	NVHXfVBjUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEV3NEWtT{BufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	MXGxPFc2PDZ3NB?=
Sf9	NYO1[IRpU2mwYYPlJGF{e2G7		MUmxJIg>	NXvWWXdQTE2VTx?=	MoDtTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCzN{DPxE1?	MkXsNVg4PTR4NUS=
Sf9	NUHrPZFFU2mwYYPlJGF{e2G7		NWPUOXA1OSCq	NYXwUYlkTE2VTx?=	MUjJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjh	M3TNcVE5PzV2NkW0
MDA-MB-361	NGrKfXlHfW6ldHnvckBCe3OjeR?=		NWWwbphOOiCq	M3Py[GROW09?	MnPWTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4xOjhizszN	MVOxPFc2PDZ3NB?=
PC3	NIDCRlNHfW6ldHnvckBCe3OjeR?=		MoHXNkBp	NV7FRXYzTE2VTx?=	NWTyell[UW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gVGM{KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCzO{DPxE1?	NHja[mcyQDd3NE[1OC=>
U87MG	Mo[5SpVv[3Srb36gRZN{[Xl?		NWrWVWJmOiCq	MonYSG1UVw>?	NELLdY1KdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	NEj4OYQyQDd3NE[1OC=>
MDA-MB-361	NImyNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml:0PVYhcA>?	MWDEUXNQ	M2nFc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvPzJizszN	M{m2b\|E5PzV2NkW0
A2780	M13KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\UXYhVQTZiaB?=	M4DEUWROW09?	NYKwTGZrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	Ml;wNVg4PTR4NUS=
PC3	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoOwPVYhcA>?	NWCx[2lvTE2VTx?=	NG\IXFFKSzVyPUCuNlgh\|ryP	M1ywW\|E5PzV2NkW0
U87MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoTEPVYhcA>?	M4m5PGROW09?	NUnwcWVSUUN3ME2wMlk2KM7:TR?=	NIfyVlMyQDd3NE[1OC=>
Sf9	MXvLbY5ie2ViQYPzZZk>		MlnxN\|AhdWmw	NYTNW5RPTE2VTx?=	MmjuTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	M1\kfVIzPTR6M{Sy
RAW 264.7	M1jpZWtqdmG\|ZTDBd5NigQ>?		NInhO3E6OCCvaX6=	MmjsSG1UVw>?	MYjJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCU1RicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlI6QCEQvF2=	M{W4PFIzPTR6M{Sy
Sf9	M4q3bGtqdmG\|ZTDBd5NigQ>?		MUixJIg>		MVrJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW0Z7IHPlcIx{KHerdHigTWM2OCCxZjCwMlAyPyEQvF2=	MkPCNlM2PDB4NEW=
Sf9	NWG2OXNLU2mwYYPlJGF{e2G7		M1KwSVEhcA>?		MnrUTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	Mkn6NlM2PDB4NEW=
Sf9	M1TidmtqdmG\|ZTDBd5NigQ>?		NFTMUIUyKGh?		Mni5TY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZB?=	NWL1S4VxOjN3NEC2OFU>
Sf9	NG\Cd\|lMcW6jc3WgRZN{[Xl?		M3va[lEhcA>?		MXLJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm	M3\BcFI{PTRyNkS1
SKOV3	NHrtVWJMcW6jc3WgRZN{[Xl?	NX7Xc25WOSEQvF2=	M13HSlEhcA>?	M1PU[mROW09?	MWHJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9v	M4PDXFI{OzZyM{S4
MCF7	NF25SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrJXZI4OSEQvF2=	MmDjPVYhcA>?	NV:yOo9sTE2VTx?=	M3LGXWdKPTB;MD6wO\|AzKM7:TR?=	NVn3fGpKOjN\|NkCzOFg>
SKOV3	M2Xsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixJO69VQ>?	MlrPPVYhcA>?	M1PGd2ROW09?	MlrsS2k2OD1yLkG0O\|Yh\|ryP	NVTLSG1NOjN\|NkCzOFg>
PC3	NHOwU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4PPc\|czKGh?	M3fLTmROW09?	M1fKVWlEPTB;MD6yPEDPxE1?	MlrONlE6QDF5MUS=
MCF7.1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnNZVE4OiCq	NHn0fpZFVVOR	M3G0TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochUEWUMjDn[Y5mKHerdHigTWM2OCCxZjCwMlI5KM7:TR?=	M{D2W\|IyQThzN{G0
MCF7-neo/Her2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\BO\|IhcA>?	NGrneoVFVVOR	MVjJR\|UxRTBwMkmg{txO	NV33eINQOjN4NkK5NFM>
MCF7-neo/Her2	NUjSN2plU2mwYYPlJGF{e2G7				MkD4TY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25iYYSgV\|Q4OyC5aYToJGlEPTBib3[gNE4xODdizszN	NWTrO3AyOjN4NkK5NFM>
PC3	NUnTcoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTOfVI4OiCq	MXjEUXNQ	NEDGOodGSzVyPUCuN\|Qh\|ryP	NFrNOJkzOTl6NU[zPS=>
MCF7.1	M4PQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2f3dlczKGh?	M3vlSGROW09?	MnHuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiRVO1NEBw\iByLkO5JO69VQ>?	NX7jfXF1OjF7OEW2N\|k>
PC3	NWDkV4psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnvbVdjPzJiaB?=	NWjyXXJ5TE2VTx?=	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCmZX\pZ4lmdnRiaX6gVHRGViC5aYToJGlEPTBib3[gNE4{QSEQvF2=	Mn:1NlAxPTB4Nkm=
MCF7.1	M1O0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVK3NkBp	MV3EUXNQ	Ml3DRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkO0JO69VQ>?	NEDre\|AzODB3ME[2PS=>
MCF7.1	M4eyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmjHO\|IhcA>?		MYXFR\|UxRTBwN{Kg{txO	MWOyNFM1PjZ3Nh?=
NCI-H1975	MVnDfZRwfG:6aXOgRZN{[Xl?		NWDX[VdMPzJiaB?=		NHewS2VKSzVyPUCuNlch\|ryP	M1nPXVI{ODV7NUS1
H460	Ml;4R5l1d3SxeHnjJGF{e2G7		NHvlOW04OiCq		NFTDXW9KSzVyPUCuPFch\|ryP	M2PGbVI{ODV7NUS1
HT-29	NF6yUo1EgXSxdH;4bYMhSXO\|YYm=		MoKwO\|IhcA>?		MnK4TWM2OD1yLk[2JO69VQ>?	NXHLXppkOjNyNUm1OFU>
HepG2	NYLLNFFKS3m2b4TvfIlkKEG\|c3H5		NYnZXmpEPzJiaB?=		MYXJR\|UxRTFizszN	MmrjNlMxPTl3NEW=
SGC7901	M4HsO2N6fG:2b4jpZ{BCe3OjeR?=		M3PvVlczKGh?		M33yU2lEPTB;MT64JO69VQ>?	MVmyN\|A2QTV2NR?=
NCI-H226	NWXJZZVzS3m2b4TvfIlkKEG\|c3H5		MUS3NkBp		NV\xRlE4UUN3ME2yMlkh\|ryP	NUPQR2plOjNyNUm1OFU>
A549	M1GxTWN6fG:2b4jpZ{BCe3OjeR?=		MXK3NkBp		MYjJR\|UxRTZwOTFOwG0>	NVLZV2Z[OjNyNUm1OFU>
U87MG	M1P1XGN6fG:2b4jpZ{BCe3OjeR?=		NIXZ[4U4OiCq		NULKbohCUUN3ME23Mlc4KM7:TR?=	MkXrNlMxPTl3NEW=
HBC4	NGnG[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;JcI9oT0l3ME2tOk4xOyCP	MkHHNlI{OzZ{NE[=
BSY1	M13wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrzcI9oT0l3ME2tOk46OCCP	M1fwcFIzOzN4MkS2
HBC5	NWO3ToFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\2TJRPdG:pR1m1NF0uPi54MDDN	NXztUYQ5OjJ\|M{[yOFY>
MCF7	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfzN2Vtd2eJSUWwQU04NjN\|IF2=	NXP3Z3JtOjJ\|M{[yOFY>
MDA-MB-231	M3vTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUX3WJdsdG:pR1m1NF0uPS52NjDN	M4DzSVIzOzN4MkS2
U251	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\sc4dIUTVyPT21MlUxKE1?	M3m5OVIzOzN4MkS2
SF268	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXiU5Ntd2eJSUWwQU02NjN7IF2=	NFO2PGQzOjN\|NkK0Oi=>
SF295	NXrJ[2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HGW4xw\0eLNUC9MVYvOzdiTR?=	MnvhNlI{OzZ{NE[=
SF539	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTsc4dIUTVyPT22MlUxKE1?	M3LpS\|IzOzN4MkS2
SNB75	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f1TYxw\0eLNUC9MVcvOTBiTR?=	NX3yXYU{OjJ\|M{[yOFY>
SNB78	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHsc4dIUTVyPT22MlUzKE1?	NGTPcHIzOjN\|NkK0Oi=>
HCC2998	NI[5bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33GeYxw\0eLNUC9MVYvOjliTR?=	NFGwXW0zOjN\|NkK0Oi=>
KM12	NWGxbVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnjcI9oT0l3ME2tOU44PiCP	MX2yNlM{PjJ2Nh?=
HT-29	NIjSSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;yUoxw\0eLNUC9MVYvOzBiTR?=	MXiyNlM{PjJ2Nh?=
HCT15	NYfKNohIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjsc4dIUTVyPT22MlEzKE1?	NF;K[WwzOjN\|NkK0Oi=>
HCT116	NX3CXXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXe3eZVkdG:pR1m1NF0uPS56NzDN	NWCzTY05OjJ\|M{[yOFY>
NCI-H23	NWTVRWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PDNYxw\0eLNUC9MVUvPzNiTR?=	M4W4flIzOzN4MkS2
NCI-H226	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrsc4dIUTVyPT22MlIyKE1?	NVe2fmdrOjJ\|M{[yOFY>
NCI-H522	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13uR4xw\0eLNUC9MVYvPThiTR?=	NVPHWINKOjJ\|M{[yOFY>
NCI-H483	NV3ES4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfsc4dIUTVyPT22MlU3KE1?	NEHkNW8zOjN\|NkK0Oi=>
A549	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7ucI9oT0l3ME2tOk4yPSCP	NVnl[HRLOjJ\|M{[yOFY>
DMS273	NVvCWJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjMO\|FodG:pR1m1NF0uPi52MzDN	M4rRVVIzOzN4MkS2
DMS114	NUGyZ2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjsc4dIUTVyPT21MlkzKE1?	Mn\4NlI{OzZ{NE[=
LOXIMVI	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfvXGxEdG:pR1m1NF0uPi5{OTDN	MWKyNlM{PjJ2Nh?=
OVCAR3	M37HN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jzV4xw\0eLNUC9MVYvPzFiTR?=	NWnIW21ZOjJ\|M{[yOFY>
OVCAR4	NYjGNJY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[2SXhodG:pR1m1NF0uPS55NjDN	MYeyNlM{PjJ2Nh?=
OVCAR5	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\6VYxw\0eLNUC9MVYvOjZiTR?=	Mo\HNlI{OzZ{NE[=
OVCAR8	NVnmTWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[0cI9oT0l3ME2tOU44OyCP	NEXqToUzOjN\|NkK0Oi=>
SKOV3	MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Do[Ixw\0eLNUC9MVYvPTJiTR?=	M37leFIzOzN4MkS2
RXF631L	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr5THlCdG:pR1m1NF0uPi56ODDN	NHzQT2MzOjN\|NkK0Oi=>
ACHN	NVniW4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvKbYRjdG:pR1m1NF0uPi5yNzDN	NIXMdHozOjN\|NkK0Oi=>
St-4	M3\Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\XdVlPdG:pR1m1NF0uPS53NjDN	MX6yNlM{PjJ2Nh?=
MKN1	NG\CSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3jTG0ydG:pR1m1NF0uPy5yODDN	NYCye5NtOjJ\|M{[yOFY>
MKN7	M1:3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvocI9oT0l3ME2tOk42OCCP	MUSyNlM{PjJ2Nh?=
MKN28	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorncI9oT0l3ME2tOU42OiCP	MmHINlI{OzZ{NE[=
MKN45	Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3lNZlUdG:pR1m1NF0uPi53NTDN	NE\SOGgzOjN\|NkK0Oi=>
MKN74	NIfFb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrsc4dIUTVyPT22MlAzKE1?	MWeyNlM{PjJ2Nh?=
DU145	M2jidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;KT\|dtd2eJSUWwQU02Njh3IF2=	M4T6OFIzOzN4MkS2
PC3	M4PWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorCcI9oT0l3ME2tOk43PiCP	NVjJeGVmOjJ\|M{[yOFY>
ES5	NH24ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTVyLkKxJI5O	M3Xq[XNCVkeHUh?=
HH	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv3dINmUUN3ME2xNVEvODhibl2=	M1vSZ3NCVkeHUh?=
MHH-PREB-1	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvvTWM2OD1zMUSuN{BvVQ>?	MmnJV2FPT0WU
NCI-H1770	NX3VOZBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLVTWM2OD1zMkOuPFYhdk1?	MYPTRW5ITVJ?
HuO9	NGnCRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vjNGlEPTB;MkC2MlAzKG6P	MXrTRW5ITVJ?
HAL-01	M3PDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTJyNj63N{BvVQ>?	MYPTRW5ITVJ?
NOS-1	NULad2xWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjEN5kzUUN3ME2yNVEvQDJibl2=	Ml7qV2FPT0WU
HGC-27	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1raWGlEPTB;MkGyMlU4KG6P	NYPJZ3FsW0GQR1XS
NB69	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HwVWlEPTB;MkS1MlI4KG6P	MXnTRW5ITVJ?
RS4-11	M1nBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nsRmlEPTB;Mk[xMlc3KG6P	MYjTRW5ITVJ?
DOK	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLONYdKSzVyPUOwNU44KG6P	M2r5ZnNCVkeHUh?=
LB2241-RCC	M{PLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFy4PJdKSzVyPUOwN{45PCCwTR?=	NV3BeYdXW0GQR1XS
NCI-H1623	NIHtc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNyND6wPEBvVQ>?	MUDTRW5ITVJ?
YH-13	M3ixSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTNyND6zNkBvVQ>?	NXizSGk3W0GQR1XS
BPH-1	NID6VYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37wUWlEPTB;M{G0JI5O	NHjGXVVUSU6JRWK=
AN3-CA	NX\qepJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnEeW5LUUN3ME2zOFAvOzdibl2=	MkXlV2FPT0WU
ES7	NIP6U\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO5dY52UUN3ME2zOFEvQTlibl2=	MX7TRW5ITVJ?
MDA-MB-175-VII	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVSyNnVHUUN3ME2zOVIvQTJibl2=	NEfGWXlUSU6JRWK=
GAMG	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULFdWlnUUN3ME2zO\|AvQDVibl2=	MWTTRW5ITVJ?
CHL-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXWTWM2OD1\|N{iuOlUhdk1?	MUHTRW5ITVJ?
NB7	NEPifoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorETWM2OD1\|OEmuPFMhdk1?	NUnCUnZrW0GQR1XS
MFE-280	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXRbnhqUUN3ME20NVgvOiCwTR?=	MVTTRW5ITVJ?
HL-60	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTR{NT63OUBvVQ>?	M{HqenNCVkeHUh?=
GCIY	NUnvRWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\K[2RKSzVyPUSzN{45KG6P	MUHTRW5ITVJ?
MDA-MB-361	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PMbmlEPTB;NEO5MlE{KG6P	MoPGV2FPT0WU
LXF-289	M1jaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;tVmlEPTB;NES4MlI4KG6P	NIDXbJVUSU6JRWK=
NBsusSR	NWLPZVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3jfIdvUUN3ME20PFgvQDVibl2=	MnrDV2FPT0WU
KU-19-19	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTVzNj6wO{BvVQ>?	NUTZdlM3W0GQR1XS
A204	NXn3UlZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7Q[pJKSzVyPUWyNk4{OyCwTR?=	M37aWHNCVkeHUh?=
LB1047-RCC	NGfmWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDjTWM2OD13MkKuPVMhdk1?	M13uc3NCVkeHUh?=
COLO-684	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmP0TWM2OD13MkOuNVEhdk1?	M3nMWnNCVkeHUh?=
PA-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DFWmlEPTB;NUOyMlQyKG6P	NGXh[phUSU6JRWK=
MG-63	M2XqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrtbHl{UUN3ME21OFEvOTFibl2=	MkDGV2FPT0WU
BHT-101	M1;TeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILnTWtKSzVyPUW0OE46PCCwTR?=	MVzTRW5ITVJ?
NKM-1	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LtfGlEPTB;NUmzMlA6KG6P	M4LIe3NCVkeHUh?=
T47D	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXK3TXRLUUN3ME21PVcvPTZibl2=	NYDC[21RW0GQR1XS
MOLT-4	M2DvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHH0Z4ZKSzVyPU[yN{43OiCwTR?=	MmHoV2FPT0WU
IGROV-1	NGS5PIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3O5cGlEPTB;NkO0MlMyKG6P	NWPrUGJLW0GQR1XS
ES4	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Ozb2lEPTB;NkO5MlU1KG6P	NU\uc21IW0GQR1XS
HuO-3N1	NEnBNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTZ2Mj6zPEBvVQ>?	M4H1dXNCVkeHUh?=
NEC8	M3rTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLjTWM2OD14NUOuOVchdk1?	MUjTRW5ITVJ?
HO-1-N-1	NHnzVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZ3OT6xO{BvVQ>?	NFjP[XpUSU6JRWK=
EPCL-272H	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rEb2lEPTB;Nki3MlIyKG6P	M33jdnNCVkeHUh?=
D-263MG	M3TESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTdzOD6xJI5O	NHLiOZJUSU6JRWK=
MV-4-11	M1S3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLj[nlKSzVyPUeyOE4{OSCwTR?=	NX[wSIpLW0GQR1XS
SK-NEP-1	NV:yZmU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDYT2dGUUN3ME23NlUvQTRibl2=	MWHTRW5ITVJ?
SW872	NVzHb3RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\IbmVEUUN3ME23NlcvQDlibl2=	NHHudZFUSU6JRWK=
P30-OHK	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHzTWM2OD15M{CuO\|Ehdk1?	Mm\UV2FPT0WU
OMC-1	NEj2RolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ixRWlEPTB;N{WxMlA6KG6P	MWDTRW5ITVJ?
LoVo	NGjCNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCxW\|huUUN3ME23O\|cvQSCwTR?=	M4H6THNCVkeHUh?=
LNCaP-Clone-FGC	NUXOSItwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HzdWlEPTB;N{m2MlM1KG6P	NYXhTZhYW0GQR1XS
L-363	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;rWWlEPTB;N{m4MlQzKG6P	M1S4WXNCVkeHUh?=
ES8	NX2xUphsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zje2lEPTB;OEGwMlUzKG6P	MnjPV2FPT0WU
697	NYWwcIkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWH4SFV6UUN3ME24N\|EvPTVibl2=	NYXoU5ZpW0GQR1XS
HSC-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTh\|OT61OEBvVQ>?	NFnmeHRUSU6JRWK=
H4	NEjhdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTh3MD64OUBvVQ>?	M2O1bXNCVkeHUh?=
QIMR-WIL	M3PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S3WWlEPTB;OE[1MlIhdk1?	MUTTRW5ITVJ?
OAW-42	M2HJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7lW2QxUUN3ME24O\|IvOTlibl2=	MVTTRW5ITVJ?
MCF7	NU\TU29QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\ud2lEPTB;OEm4MlU6KG6P	M4riVHNCVkeHUh?=
SCC-25	NXOzW2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LRSWlEPTB;OUG0MlE6KG6P	MWfTRW5ITVJ?
NCI-H1563	NXuwPHZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorsTWM2OD17MUWuPVkhdk1?	Mnr4V2FPT0WU
OVCAR-5	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ywRWlEPTB;OUSwMlE4KG6P	MkH2V2FPT0WU
HDLM-2	NXOz[25UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLpTWM2OD17NEmuNkBvVQ>?	NXK3NYNUW0GQR1XS
NB5	NHvE[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LUWmlEPTB;OUW2MlYhdk1?	MnLkV2FPT0WU
NCI-H292	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rBOmlEPTB;OUe0MlMzKG6P	NVW4dlR{W0GQR1XS
A101D	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HhWmlEPTB;OUmwMlE6KG6P	MXHTRW5ITVJ?
NCI-H1648	NU\zXXBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjOTWM2OD17OUiuOVEhdk1?	M3jkN3NCVkeHUh?=
EKVX	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzCXnBOUUN3ME2xMlAyOjlizszN	M2HmPXNCVkeHUh?=
SW1710	M1Hpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPqSXFKSzVyPUGuNFQzOzNizszN	NHn6[W1USU6JRWK=
WM-115	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwME[2OVYh\|ryP	NIfQUFBUSU6JRWK=
CAL-54	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwMEewPFEh\|ryP	M2LuOHNCVkeHUh?=
TGBC24TKB	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfmVXZKSzVyPUGuNFgxPDVizszN	NHjweFNUSU6JRWK=
NCI-H520	NYTNd5psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwMEi5Olch\|ryP	MnnHV2FPT0WU
D-423MG	NFjt[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF74[5RKSzVyPUGuNFk6PjJizszN	M3;sOHNCVkeHUh?=
BFTC-905	MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULjeFFPUUN3ME2xMlE{PDR7IN88US=>	NILubFFUSU6JRWK=
HT	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwMUO0O\|gh\|ryP	MmjQV2FPT0WU
CTB-1	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfmTHNKSzVyPUGuNVQzQTNizszN	NWPWWWJCW0GQR1XS
Hs-578-T	NFXwTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjYO21KSzVyPUGuNVk2PjVizszN	Mnz3V2FPT0WU
HuH-7	M2\yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XH[2lEPTB;MT6yNFk1QSEQvF2=	NGfxSoxUSU6JRWK=
LB996-RCC	NHTrUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTBUHB3UUN3ME2xMlIzOTd5IN88US=>	NELWdHJUSU6JRWK=
KYSE-270	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[4fWlEPTB;MT6yPVc{PCEQvF2=	MWfTRW5ITVJ?
A4-Fuk	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULBVllSUUN3ME2xMlI6QTl\|IN88US=>	MYHTRW5ITVJ?
A498	M{LV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnZfHBxUUN3ME2xMlMxPDd2IN88US=>	NH3BS4pUSU6JRWK=
SK-MEL-1	NXzKTGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDGfZRKSzVyPUGuN\|A3PzlizszN	MXHTRW5ITVJ?
AU565	NVLEWVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXVTWM2OD1zLkOxPFY{KM7:TR?=	MVzTRW5ITVJ?
Saos-2	NXyzeI57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXf3Z\|JtUUN3ME2xMlM{OjB3IN88US=>	M1HkfXNCVkeHUh?=
A549	NGjMSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;STWM2OD1zLkO5PVch\|ryP	MoTQV2FPT0WU
BFTC-909	NIDyV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwNEOzNFUh\|ryP	MnTQV2FPT0WU
MDA-MB-415	M4HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4f3SmlEPTB;MT60PFY6OiEQvF2=	NEDU[nVUSU6JRWK=
639-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlT5TWM2OD1zLkWwNlQ2KM7:TR?=	M2e4TXNCVkeHUh?=
A704	NF;oVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHwVnVVUUN3ME2xMlUxPzh3IN88US=>	MWLTRW5ITVJ?
PANC-03-27	NHrBdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHZVo1KSzVyPUGuOVE1ODhizszN	MYPTRW5ITVJ?
SK-MEL-28	M4\lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnLTWM2OD1zLkW2NFg2KM7:TR?=	MUnTRW5ITVJ?
Ramos-2G6-4C10	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjsW\|RwUUN3ME2xMlYxPzR4IN88US=>	MoPWV2FPT0WU
HuP-T4	M2[4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED5XWlKSzVyPUGuOlA4PzhizszN	NWrxZoVXW0GQR1XS
VA-ES-BJ	NX\EV\|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTFwNkGyO{DPxE1?	NULJN3gzW0GQR1XS
EFM-19	NH:3TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX[zO5Z3UUN3ME2xMlYyQDFizszN	MX\TRW5ITVJ?
G-401	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Lx[2lEPTB;MT62NlE3PCEQvF2=	MWLTRW5ITVJ?
D-566MG	NUi1TYJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NICySVJKSzVyPUGuOlI2OyEQvF2=	M3XsdXNCVkeHUh?=
JVM-3	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTFwNkS4O\|Uh\|ryP	NETEZ\|NUSU6JRWK=
TK10	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXrTWM2OD1zLk[3NFg{KM7:TR?=	MX7TRW5ITVJ?
BT-20	M4nUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvrcnhKUUN3ME2xMlY5QTB{IN88US=>	MmWwV2FPT0WU
EGI-1	NGTTNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPFZoVTUUN3ME2xMlg1PzBzIN88US=>	NFXLcXpUSU6JRWK=
EW-16	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTnNGZKSzVyPUGuPFUyQDJizszN	MlrRV2FPT0WU
NCI-H2228	MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjDRZFnUUN3ME2xMlg2OjB\|IN88US=>	M{LKT3NCVkeHUh?=
BB49-HNC	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\4dJRKSzVyPUGuPFg3QTJizszN	MULTRW5ITVJ?
G-402	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3LTWM2OD1zLki5O\|k4KM7:TR?=	NFfYdJFUSU6JRWK=
NCI-H526	NEjhVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4q4UmlEPTB;MT65NVM6KM7:TR?=	NYHKR2JNW0GQR1XS
ME-180	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTTU2JKSzVyPUGuPVM1PzdizszN	M{XFWHNCVkeHUh?=
PFSK-1	M1mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTFwOUS0OVgh\|ryP	MnPDV2FPT0WU
TYK-nu	NEDnZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPoenBKSzVyPUGuPVU5OjNizszN	MV3TRW5ITVJ?
HOS	NGP4VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTv[JhqUUN3ME2xMlk4QTR6IN88US=>	MkT1V2FPT0WU
T98G	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV76c\|NtUUN3ME2xMlk6ODB4IN88US=>	NYnXNIxIW0GQR1XS
SK-MES-1	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPkUGttUUN3ME2yMlAyOzN{IN88US=>	NWmwVmZ3W0GQR1XS
SNB75	NYXpNYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPuTWM2OD1{LkCxOVQyKM7:TR?=	M4HRenNCVkeHUh?=
LAMA-84	M4Lvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37KS2lEPTB;Mj6wNlY5QSEQvF2=	M1LmSHNCVkeHUh?=
CAL-39	NFTYWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJwMEOyPEDPxE1?	NHfBeWdUSU6JRWK=
LOXIMVI	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvlR2ZKSzVyPUKuNFQxQDRizszN	MnW1V2FPT0WU
NH-12	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJwMEW0NlQh\|ryP	M3;W[XNCVkeHUh?=
NCI-H1048	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnoUndxUUN3ME2yMlExPTJizszN	MmDjV2FPT0WU
KS-1	NWfPVG56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7ne\|VKSzVyPUKuNVExODFizszN	MnjXV2FPT0WU
NCI-N87	NYrXVoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJwMUOzPFQh\|ryP	NEDaOFBUSU6JRWK=
CHP-212	M3;GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJwMUi0OFIh\|ryP	NFXnUpBUSU6JRWK=
HCC1419	NXnabJdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDrTWM2OD1{LkKxNVE2KM7:TR?=	MU\TRW5ITVJ?
ES1	NX60eZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrCZopKSzVyPUKuNlE{OjZizszN	M4fMS3NCVkeHUh?=
NCI-H2030	NYLoU5NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTJwMkSxNlMh\|ryP	MlXuV2FPT0WU
EW-22	NFTpcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJwMkWwOlch\|ryP	MmXwV2FPT0WU
A431	NH63VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX22ZZFFUUN3ME2yMlI4OzV2IN88US=>	M{LxPHNCVkeHUh?=
SF126	M3vaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfMTWM2OD1{LkOwOlI2KM7:TR?=	MmHZV2FPT0WU
SF295	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJwM{G1NlQh\|ryP	NET3cmFUSU6JRWK=
D-502MG	NXTpZ4pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPPTWM2OD1{LkOyOFYyKM7:TR?=	NXXhfI9nW0GQR1XS
HCC2157	M2OybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDCWJBoUUN3ME2yMlMzQTJ5IN88US=>	MUnTRW5ITVJ?
D-283MED	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vCPWlEPTB;Mj6zOVkzPiEQvF2=	MlHpV2FPT0WU
SNU-423	NGfCNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL1SXFKSzVyPUKuOFAyPzFizszN	NYDLcYt{W0GQR1XS
SK-LU-1	NIS2XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJwNES1PFYh\|ryP	MUnTRW5ITVJ?
22RV1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfrOFFYUUN3ME2yMlQ2PjF5IN88US=>	MXzTRW5ITVJ?
SW1088	M3fp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHXTWM2OD1{LkS5NlE{KM7:TR?=	NH3KU3hUSU6JRWK=
HT-3	M1PoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;vcphKSzVyPUKuOFkzPTlizszN	NIL5UoxUSU6JRWK=
NCI-H1666	NF;KboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJwNUGxNFQh\|ryP	MXzTRW5ITVJ?
EM-2	NXvneFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrRPZVKSzVyPUKuOVEyPjlizszN	NXLjb3pLW0GQR1XS
SNU-449	NWTPc5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml6xTWM2OD1{LkW3NFE1KM7:TR?=	MXLTRW5ITVJ?
786-0	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zSNmlEPTB;Mj61PVI{QCEQvF2=	MkjuV2FPT0WU
SKG-IIIa	NHrMUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJwNkW5N\|kh\|ryP	M{TiNnNCVkeHUh?=
MEL-HO	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfNTWM2OD1{Lk[3OlM1KM7:TR?=	MXvTRW5ITVJ?
LCLC-97TM1	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfITYNKSzVyPUKuOlkzPjdizszN	MkLnV2FPT0WU
MKN7	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJwN{C3OVQh\|ryP	NHHScHJUSU6JRWK=
5637	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrRO3dKSzVyPUKuO\|ExOzVizszN	NFfSeJBUSU6JRWK=
HOP-92	M3TxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzOcJdjUUN3ME2yMlc1PzF5IN88US=>	MVnTRW5ITVJ?
MDA-MB-157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrRNJBKSzVyPUKuPFIxOjNizszN	MWTTRW5ITVJ?
NB12	NGnHVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TmW2lEPTB;Mj64OFkyPCEQvF2=	M2LKW3NCVkeHUh?=
DMS-273	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X1dmlEPTB;Mj64OlQ4KM7:TR?=	NXrVeW1YW0GQR1XS
HCC70	NYL4TXVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHiZVF3UUN3ME2yMlg3PTh7IN88US=>	MXTTRW5ITVJ?
YKG-1	NEjRZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XLbWlEPTB;Mz6wN\|c5PyEQvF2=	MXjTRW5ITVJ?
NCI-H28	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjWTWM2OD1\|LkC1NlkyKM7:TR?=	MmOxV2FPT0WU
HN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3[3NWlEPTB;Mz6wOlY{PiEQvF2=	MVzTRW5ITVJ?
HT-1080	NUPaN\|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHCeJRKSzVyPUOuNFg3ODZizszN	MXjTRW5ITVJ?
HPAF-II	NXTXcYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfpb5pKSzVyPUOuNVAxPjhizszN	MUTTRW5ITVJ?
U-2-OS	NIPFeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1yyT2lEPTB;Mz6xN\|c5OiEQvF2=	NEfZXmRUSU6JRWK=
SNU-387	NEXKXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[5UmlEPTB;Mz6xOlM3PCEQvF2=	NWK3emt1W0GQR1XS
Becker	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrFTWM2OD1\|LkG2PFA5KM7:TR?=	MknqV2FPT0WU
BHY	NXv5S4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnlSHBKSzVyPUOuNlU2PzFizszN	NE\rRWpUSU6JRWK=
HTC-C3	M1vwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPiTWM2OD1\|LkK5N\|UzKM7:TR?=	M2q1NHNCVkeHUh?=
M14	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;qbVNRUUN3ME2zMlMxPjZ\|IN88US=>	NVT1XHM4W0GQR1XS
COR-L23	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPlOohKSzVyPUOuN\|czPzlizszN	MoPzV2FPT0WU
C32	M33pbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF2zVJFKSzVyPUOuOFE2ODhizszN	Mm\4V2FPT0WU
Mewo	NVPQcZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDnXIhKSzVyPUOuOFIyQDJizszN	Ml7JV2FPT0WU
TE-8	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2q2O2lEPTB;Mz60PFI2QSEQvF2=	NWn3cIFZW0GQR1XS
RPMI-2650	NGLPcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTNwNkC2N\|ch\|ryP	MojwV2FPT0WU
AGS	M2LFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHjTWM2OD1\|Lk[yOFY1KM7:TR?=	M376PHNCVkeHUh?=
MZ2-MEL	NX\ybVFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTNwNk[xN\|gh\|ryP	NID0OG5USU6JRWK=
Calu-3	NYTBWJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXib3dKSzVyPUOuO\|EzQDdizszN	NV;jUZBrW0GQR1XS
SJSA-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\OdmlEPTB;Mz63NVMyPSEQvF2=	MY\TRW5ITVJ?
SW962	NXnLcGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;IXoc5UUN3ME2zMlczPjN4IN88US=>	NHqyVm5USU6JRWK=
PC-14	NI\KdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmraTWM2OD1\|LkezNlIzKM7:TR?=	NFzoWFlUSU6JRWK=
SW1573	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTNwN{WzOFgh\|ryP	MmXaV2FPT0WU
769-P	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\GV5dKSzVyPUOuPFI4PDNizszN	MlPFV2FPT0WU
KNS-62	NV7MNlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vpOGlEPTB;Mz65NlM{QCEQvF2=	NYrmWJpbW0GQR1XS
NCI-H747	NIDj[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\jTWM2OD12LkC1OlM5KM7:TR?=	M4PKbnNCVkeHUh?=
LN-405	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\xW5ZwUUN3ME20MlE2PzJ6IN88US=>	MYTTRW5ITVJ?
OVCAR-8	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV:y[IJKUUN3ME20MlIzPTR\|IN88US=>	NYjWPJFnW0GQR1XS
DMS-114	M4K3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;zZVhKSzVyPUSuNlM5QTFizszN	M3PmdHNCVkeHUh?=
NCI-H2126	NYXiSmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;vXYc2UUN3ME20MlI1PTV6IN88US=>	NEnIb5lUSU6JRWK=
TCCSUP	NEPiZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTRwMkS3PFgh\|ryP	MVnTRW5ITVJ?
SK-N-FI	NWDKVIU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTRwMkWzN\|Ih\|ryP	NFHWelRUSU6JRWK=
HCE-4	NHHlRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\0ZmlEPTB;ND6yO\|E6PyEQvF2=	M4nuRXNCVkeHUh?=
DK-MG	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorsTWM2OD12LkOwN\|kh\|ryP	NULJPW1wW0GQR1XS
RO82-W-1	NYLtUZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPPRpFKSzVyPUSuN\|I2QDRizszN	MVrTRW5ITVJ?
A2780	M2H0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjWU4lnUUN3ME20MlM3Pjh{IN88US=>	MXzTRW5ITVJ?
ETK-1	NFG5UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zsTmlEPTB;ND6zO\|A2OiEQvF2=	MoftV2FPT0WU
FADU	NFzPRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC5bGRKSzVyPUSuN\|c1PjdizszN	MV3TRW5ITVJ?
CAL-12T	NWjJSJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TSNGlEPTB;ND60NVQyOyEQvF2=	NW\CVZFzW0GQR1XS
647-V	NXnKSYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLmTWM2OD12LkS0NFIzKM7:TR?=	MlnJV2FPT0WU
TGBC1TKB	NFX5cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvxTWM2OD12LkS1NVE{KM7:TR?=	MV;TRW5ITVJ?
LU-99A	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXBTWM2OD12LkS2NFYh\|ryP	M33wWnNCVkeHUh?=
CAL-33	NUXyVWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTRwNUK0OVYh\|ryP	MljiV2FPT0WU
LU-134-A	NYfTNG1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTRwNUK3OFUh\|ryP	NXjVUWY2W0GQR1XS
NCI-H1355	M4m1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3QRVlDUUN3ME20MlU2OTR4IN88US=>	NWT0To5yW0GQR1XS
RPMI-7951	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPsTWM2OD12LkW3NFAzKM7:TR?=	NVzQeW9WW0GQR1XS
TE-1	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LNUGlEPTB;ND62OlE1OyEQvF2=	MmjJV2FPT0WU
OE33	M4PHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrwTWM2OD12LkewOVEyKM7:TR?=	MkDKV2FPT0WU
CAL-51	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjHOpVDUUN3ME20MlcyODh{IN88US=>	NXrae4VNW0GQR1XS
SW1783	NHOwTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTRwN{WzNFgh\|ryP	NGTLUWhUSU6JRWK=
BT-474	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:4TWM2OD12Lke2N\|g1KM7:TR?=	NEnRT5NUSU6JRWK=
KYSE-520	NFrMb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTGO2xMUUN3ME20Mlg4Ozl{IN88US=>	MX\TRW5ITVJ?
8-MG-BA	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XVRWlEPTB;ND64PFU2PyEQvF2=	M1zyeHNCVkeHUh?=
IA-LM	NH;TeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33FcmlEPTB;ND65PVQ{PSEQvF2=	M2jRSnNCVkeHUh?=
SW954	NXLnVHZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XvNGlEPTB;ND65PVQ1OyEQvF2=	M2DueXNCVkeHUh?=
RPMI-8226	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLTdHMzUUN3ME21MlA2PDZzIN88US=>	M2jLd3NCVkeHUh?=
MKN1	M{nndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTVwMEe5Nlch\|ryP	M3jPSnNCVkeHUh?=
A375	NHvXcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvGTWM2OD13LkC5NlU3KM7:TR?=	NWHCb\|BWW0GQR1XS
8305C	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37heWlEPTB;NT6wPVg5PyEQvF2=	M1ryd3NCVkeHUh?=
CAL-62	NF;OZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;aTWM2OD13LkG4NlU6KM7:TR?=	M4\tZXNCVkeHUh?=
NB10	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzqbFFKSzVyPUWuNlI4PDRizszN	MonzV2FPT0WU
OC-314	NHnVVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTVwM{e0OFQh\|ryP	NH\zUI9USU6JRWK=
PSN1	NInaW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL4NlVKSzVyPUWuN\|gzQDZizszN	MofyV2FPT0WU
GR-ST	M1fBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHBTWM2OD13LkO4N\|IzKM7:TR?=	MYjTRW5ITVJ?
P12-ICHIKAWA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e0bWlEPTB;NT60NFEh\|ryP	MVTTRW5ITVJ?
NCI-H1092	NHTVflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli1TWM2OD13LkSxNVQ5KM7:TR?=	MVfTRW5ITVJ?
SCC-4	NF\MOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTVwNEGzOVUh\|ryP	MUTTRW5ITVJ?
TE-6	M4jLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPCTWM2OD13LkSxPFE3KM7:TR?=	Mm\jV2FPT0WU
DOHH-2	M{fFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfYd41{UUN3ME21MlQzOjR6IN88US=>	NFTMNo9USU6JRWK=
SW684	M3Hj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmGyTWM2OD13Lk[2N\|g2KM7:TR?=	M4PNTnNCVkeHUh?=
CP50-MEL-B	NEfrUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHoOG0xUUN3ME21MlY5Pjh2IN88US=>	Ml3qV2FPT0WU
UM-UC-3	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL1TWM2OD13LkeyNlMyKM7:TR?=	MoX5V2FPT0WU
LC-2-ad	NYnlPZZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDHXmFKSzVyPUWuO\|gzPTFizszN	NEfSPVJUSU6JRWK=
PC-3	NUPyS\|NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MomyTWM2OD13LkmxOlE2KM7:TR?=	NX;mbpJSW0GQR1XS
CAN	NUjQV2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTVwOUK4NkDPxE1?	NWSyR2p4W0GQR1XS
ESS-1	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHT6W2JKSzVyPUWuPVc5PjlizszN	NWq1RoJWW0GQR1XS
ATN-1	Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDW[nFIUUN3ME22MlA2PTZ6IN88US=>	MkDqV2FPT0WU
BxPC-3	NIDRVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTZwMEiyNVkh\|ryP	M{f3fXNCVkeHUh?=
KYSE-150	NHTHOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZwMUK0O\|Yh\|ryP	M4exZXNCVkeHUh?=
RPMI-8866	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rIbmlEPTB;Nj6xPVE3OyEQvF2=	MkPYV2FPT0WU
SW780	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfmOolKSzVyPU[uNlA1OiEQvF2=	MoWzV2FPT0WU
A388	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XMS2lEPTB;Nj6yN\|EyPSEQvF2=	NVP3ZYFwW0GQR1XS
NCI-H1437	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnE[XBKSzVyPU[uNlQxPzNizszN	NVrxPYF{W0GQR1XS
NCI-H1755	NFvyV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu4TWM2OD14LkO2OlEzKM7:TR?=	MnW3V2FPT0WU
LS-123	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\ROGlEPTB;Nj60NFUzOSEQvF2=	M3;CW3NCVkeHUh?=
CaR-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\oPG1KSzVyPU[uOFY{PzNizszN	NVv2dZBQW0GQR1XS
RT-112	NX7yNY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF70XpZKSzVyPU[uOlA{OzhizszN	MonuV2FPT0WU
CGT	NGDIXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\WRWlEPTB;Nj63N\|Y5OSEQvF2=	NFPGWmZUSU6JRWK=
SW626	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTZwN{O5OFYh\|ryP	NHLXZW5USU6JRWK=
AsPC-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTZwN{S1NFch\|ryP	NEnTZolUSU6JRWK=
SBC-5	NEfWXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmGzTWM2OD14Lkm3Nlk4KM7:TR?=	Ml62V2FPT0WU
SF539	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jufWlEPTB;Nj65PVM{OyEQvF2=	M2nsZnNCVkeHUh?=
TI-73	NFXBUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LBTWlEPTB;Nz6wOlI5PSEQvF2=	NF62d5JUSU6JRWK=
MHH-ES-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfuV4RKSzVyPUeuNFc4PjJizszN	MoLDV2FPT0WU
KYSE-510	NEDOVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTdwMEi0N\|Ih\|ryP	M1Gxd3NCVkeHUh?=
EW-1	NH3sOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HOPWlEPTB;Nz6zOlk6PiEQvF2=	NYDXWXBtW0GQR1XS
SK-OV-3	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDkZ29rUUN3ME23MlM6PDN{IN88US=>	M1XIWnNCVkeHUh?=
MC-IXC	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17ibmlEPTB;Nz60NVk4OiEQvF2=	NI\MUHBUSU6JRWK=
HSC-2	NHXOSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTdwNEK3NFUh\|ryP	M{PxbnNCVkeHUh?=
NCI-H2342	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzZfXI{UUN3ME23MlUyPDlizszN	NULDcWR[W0GQR1XS
NCI-H1792	M1nxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrGTWM2OD15LkWxO\|EyKM7:TR?=	NFzmSHlUSU6JRWK=
HT-1376	NX7XOpVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33Dc2lEPTB;Nz64O\|c4QCEQvF2=	M3vzVnNCVkeHUh?=
EW-13	M33wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M133NmlEPTB;Nz64PVk4PyEQvF2=	NF;MfJFUSU6JRWK=
no-11	NVPH[\|diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTdwOUCxO\|Qh\|ryP	M1TnOHNCVkeHUh?=
Daoy	M{XtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ftSmlEPTB;Nz65OFMzOSEQvF2=	NEWySoRUSU6JRWK=
COLO-800	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRThwMESxOlIh\|ryP	MnfNV2FPT0WU
GB-1	NGn6NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPrT4RKSzVyPUiuNFY2PjVizszN	MVfTRW5ITVJ?
SJRH30	NEW3UHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPj[mQ5UUN3ME24MlE2QDd6IN88US=>	NHv4ZYNUSU6JRWK=
NCI-H2291	NYXC[GRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7JNI5nUUN3ME24MlI6OTh5IN88US=>	NUnER5d4W0GQR1XS
J82	M3LaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRThwMkm0PVEh\|ryP	NX7M[Vc6W0GQR1XS
NCI-H596	NGX3T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjhblJmUUN3ME24MlMyPDV\|IN88US=>	NGLoZ3BUSU6JRWK=
RERF-LC-MS	M4rzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\1O4JKSzVyPUiuN\|Q5PTZizszN	MmXmV2FPT0WU
RH-18	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRThwM{WwOFYh\|ryP	MoLWV2FPT0WU
SW48	NHm1eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;CTWM2OD16LkW5OFU{KM7:TR?=	NFP2[pZUSU6JRWK=
RD	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvzTpFpUUN3ME24MlU6OzlzIN88US=>	NF3DfphUSU6JRWK=
MS-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRThwNkGzPFch\|ryP	NGLubYhUSU6JRWK=
ES6	NITjOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRThwN{OxNVkh\|ryP	MUDTRW5ITVJ?
TE-12	M4TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRThwN{e1NFUh\|ryP	NWPEZpZYW0GQR1XS
DBTRG-05MG	NV3CUpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjaT21zUUN3ME24MlkyOjF5IN88US=>	NULXTFd[W0GQR1XS
KINGS-1	NUnBbmt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL4T\|ZKSzVyPUiuPVI6OzhizszN	NVPp[GV{W0GQR1XS
HLE	NG\HNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3LTWM2OD16LkmzO\|g2KM7:TR?=	MlflV2FPT0WU
MHH-NB-11	NU\Tfpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjoNoVUUUN3ME25MlAyQDN7IN88US=>	MYDTRW5ITVJ?
U-87-MG	M4PTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj6TJZOUUN3ME25MlI1OzJzIN88US=>	NE[0WHNUSU6JRWK=
MN-60	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnezTWM2OD17LkK0OVQzKM7:TR?=	NUm5ZZZNW0GQR1XS
SAS	NWGw[XZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33zR2lEPTB;OT6yOVU5OSEQvF2=	NF7LVGhUSU6JRWK=
NCI-H446	M1;PZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIW5ZWZKSzVyPUmuN\|YyKM7:TR?=	MlSyV2FPT0WU
C-33-A	M4faNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XxNmlEPTB;OT60N\|k5QCEQvF2=	NFj4NFJUSU6JRWK=
RXF393	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7wc\|dKSzVyPUmuOFcxODJizszN	M4LvWHNCVkeHUh?=
CGTH-W-1	NWTwVmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTlwNEmzPFQh\|ryP	MknTV2FPT0WU
RCM-1	M2ryWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTlwNkO4NFEh\|ryP	NXPB[Xh1W0GQR1XS
SN12C	NHfRXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoWxTWM2OD17Lk[1N\|M5KM7:TR?=	M1rUSHNCVkeHUh?=
KLE	NFPVd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzhTWM2OD17LkewNFA6KM7:TR?=	NIfIT3dUSU6JRWK=
EFO-21	M3e1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYC1RpB2UUN3ME25Mlc4Ozh{IN88US=>	MXzTRW5ITVJ?
KYSE-70	NWH3T21WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLCU2pYUUN3ME25Mlg5ODFzIN88US=>	NUDNTI85W0GQR1XS
D-247MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFyLkC1Olgh\|ryP	MnPmV2FPT0WU
MPP-89	M{Lobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvTUVNKSzVyPUGwMlA6PDZizszN	M2LzU3NCVkeHUh?=
RVH-421	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFyLkG1NFUh\|ryP	MlXaV2FPT0WU
NCI-H460	NVPyc2RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPPdYJKSzVyPUGwMlI5ODZizszN	M2Llc3NCVkeHUh?=
NOMO-1	NWPSXpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\kTWM2OD1zMD6zOVMzKM7:TR?=	NGHiVYdUSU6JRWK=
DEL	M2rMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHtco9KSzVyPUGwMlM4QTRizszN	MYDTRW5ITVJ?
HT55	M1S1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjBT4tjUUN3ME2xNE43OjB3IN88US=>	MYnTRW5ITVJ?
MC116	NGS1T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYH5eJZxUUN3ME2xNE43PjV3IN88US=>	MVHTRW5ITVJ?
BB30-HNC	NFPXW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFyLk[2PUDPxE1?	NX;CeZRYW0GQR1XS
DJM-1	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTFyLk[5OFkh\|ryP	MX3TRW5ITVJ?
ZR-75-30	NUDxV21vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PoVmlEPTB;MUCuPVQ1OSEQvF2=	MVfTRW5ITVJ?
U-118-MG	NX3CR\|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nLXGlEPTB;MUCuPVg6PiEQvF2=	M4XYU3NCVkeHUh?=
MSTO-211H	NX;NbVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;UTHpKSzVyPUGxMlA4OTZizszN	M1XmbXNCVkeHUh?=
SW837	MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTFzLkC5OFkh\|ryP	MWPTRW5ITVJ?
HuCCT1	M4Dzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LWNGlEPTB;MUGuNVI5OSEQvF2=	MWXTRW5ITVJ?
RCC10RGB	NXnTcHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFzLkGzOUDPxE1?	MUnTRW5ITVJ?
NMC-G1	M1zqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrmOWxLUUN3ME2xNU4yPDl\|IN88US=>	MoPMV2FPT0WU
NCI-H650	NITwOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XVb2lEPTB;MUGuN\|c6PCEQvF2=	MoPkV2FPT0WU
HEC-1	NIDidpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2W0bGlEPTB;MUGuOFMzQCEQvF2=	M1vxV3NCVkeHUh?=
DU-4475	NV3nWHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHxTWM2OD1zMT63N\|k{KM7:TR?=	NIjifVVUSU6JRWK=
DSH1	M3vPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjzTWM2OD1zMT63OlA3KM7:TR?=	MnuwV2FPT0WU
HCC1569	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nBO2lEPTB;MUGuO\|Y4QCEQvF2=	M1m1W3NCVkeHUh?=
HCC1187	NWnm[plvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PxOmlEPTB;MUGuPFU5QCEQvF2=	NYjzTHVkW0GQR1XS
EW-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;mTWM2OD1zMT65OFc1KM7:TR?=	NVrnR5N1W0GQR1XS
LB2518-MEL	NEXnSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV36SVFqUUN3ME2xNk4xPTlizszN	M1zTTXNCVkeHUh?=
KALS-1	NGnGN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jN[mlEPTB;MUKuPFU2OyEQvF2=	MVzTRW5ITVJ?
8505C	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2X5PGlEPTB;MUKuPFg2KM7:TR?=	NWjRT2l5W0GQR1XS
SK-N-DZ	NGfjeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DQdmlEPTB;MUOuNFQ2OyEQvF2=	M1;BTXNCVkeHUh?=
CHP-134	M4jmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[xeGlEPTB;MUOuNVE2QCEQvF2=	NHO5OWNUSU6JRWK=
HCE-T	NHPhRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTMTWM2OD1zMz6yN\|Y1KM7:TR?=	Mkn1V2FPT0WU
LB-831-BLC	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF\|Lk[yOFYh\|ryP	NG\zc3ZUSU6JRWK=
OVCAR-4	M4nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHxTWM2OD1zMz62OVI1KM7:TR?=	MlXyV2FPT0WU
SW756	NHyxeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\td\|dKSzVyPUGzMlczPDZizszN	M2X2VHNCVkeHUh?=
OCUB-M	M{LBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W0NmlEPTB;MUOuPFE2PiEQvF2=	NUXwNVBCW0GQR1XS
SW982	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTF\|LkiyO\|Yh\|ryP	MYnTRW5ITVJ?
DB	M3;XW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXWTWM2OD1zMz64N\|g1KM7:TR?=	M3rFVnNCVkeHUh?=
H-EMC-SS	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Dy[mlEPTB;MUOuPVE{QSEQvF2=	Ml3xV2FPT0WU
VMRC-RCZ	NHqwXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF2LkCwNVUh\|ryP	M3vSSnNCVkeHUh?=
CAKI-1	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mli3TWM2OD1zND6wNVMzKM7:TR?=	NGL6VYpUSU6JRWK=
GI-1	NXOxOGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7VbItKSzVyPUG0MlA3PThizszN	MkfUV2FPT0WU
Ca9-22	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfUeY9KSzVyPUG0MlYxPTRizszN	NH7l[pNUSU6JRWK=
TE-5	NFuzSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF2LkeyNFgh\|ryP	MnHOV2FPT0WU
EFO-27	NXHGXYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XGWGlEPTB;MUSuO\|YzOiEQvF2=	MWPTRW5ITVJ?
CAL-72	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLkTWM2OD1zND63O\|g{KM7:TR?=	MkjYV2FPT0WU
GP5d	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnUfoxKSzVyPUG1MlA1PzRizszN	NULwSIs4W0GQR1XS
CAS-1	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonwTWM2OD1zNT6wOlYh\|ryP	MW\TRW5ITVJ?
A2058	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3X2cGlEPTB;MUWuOVY{QCEQvF2=	MWfTRW5ITVJ?
PANC-08-13	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm1R4JWUUN3ME2xOU43QDV7IN88US=>	MWnTRW5ITVJ?
Detroit562	NILKbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M122b2lEPTB;MUWuPVE{QSEQvF2=	MXLTRW5ITVJ?
PANC-10-05	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfu[nJJUUN3ME2xOk4xQDJzIN88US=>	NI\OS\|lUSU6JRWK=
KOSC-2	NV\jcphVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXTVpRmUUN3ME2xOk4yOTJ3IN88US=>	NV;CdpZDW0GQR1XS
GT3TKB	NXLUT2o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fWRWlEPTB;MU[uNVk5OSEQvF2=	MoPWV2FPT0WU
KM-H2	M4\Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED1NWdKSzVyPUG2MlM3PDZizszN	NILBb5RUSU6JRWK=
LB771-HNC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n2UmlEPTB;MU[uOFQzOiEQvF2=	Ml\TV2FPT0WU
SF268	NWqybYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF4LkS1NkDPxE1?	MXTTRW5ITVJ?
OE19	NE\IdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1K0dmlEPTB;MU[uOVI1KM7:TR?=	M2r3dHNCVkeHUh?=
MLMA	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTF4LkW1O\|Eh\|ryP	MYDTRW5ITVJ?
MDA-MB-231	NVX6e2cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV62cZJOUUN3ME2xOk44OTN4IN88US=>	NHOzOY1USU6JRWK=
TGW	NV7wZ5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\l[JZsUUN3ME2xOk45OTB{IN88US=>	NYfnN2l[W0GQR1XS
MDA-MB-453	M1zzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPKTWM2OD1zNz6wNFA{KM7:TR?=	MXLTRW5ITVJ?
SNU-C2B	NYPDWYs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjWTWM2OD1zNz6wNlM4KM7:TR?=	MYrTRW5ITVJ?
A427	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfCRYhKSzVyPUG3MlI{OzRizszN	NWPXV3BkW0GQR1XS
SK-MEL-2	M2ewTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF5LkOyNVMh\|ryP	NVrGXGk3W0GQR1XS
KURAMOCHI	M{XBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWO1XVlUUUN3ME2xO{4{QDl5IN88US=>	MkGyV2FPT0WU
IST-MEL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXuXIJQUUN3ME2xO{46OTh{IN88US=>	MW\TRW5ITVJ?
NCI-H1793	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4KxRmlEPTB;MUiuNVU5OSEQvF2=	MoLzV2FPT0WU
HCC1395	M4Ls[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF6LkW2NVEh\|ryP	M4e0fHNCVkeHUh?=
NUGC-3	MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TNZWlEPTB;MUiuOlU5PCEQvF2=	MWfTRW5ITVJ?
BB65-RCC	NGPTdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\pfmlEPTB;MUiuOlY6KM7:TR?=	NF;ETGtUSU6JRWK=
RMG-I	NUfKXlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfrTWM2OD1zOD63N\|gzKM7:TR?=	NWfqR3B6W0GQR1XS
LS-513	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvyTWM2OD1zOD65NlI5KM7:TR?=	M4Da[3NCVkeHUh?=
MFM-223	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF7LkC3NVYh\|ryP	NFHLN2tUSU6JRWK=
NCI-H727	NWruV4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF7LkOyPVUh\|ryP	MoTnV2FPT0WU
KP-4	NWDk[VBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTRTWM2OD1zOT64OVMyKM7:TR?=	MVTTRW5ITVJ?
NB13	M4juTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLBTWM2OD1zOT64PFM6KM7:TR?=	NWHZdWtRW0GQR1XS
UACC-893	M1LES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHx[3BjUUN3ME2xPU46PzV5IN88US=>	NX\qW5ZvW0GQR1XS
HT-1197	M1GwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jIbmlEPTB;MkCuNlk2QCEQvF2=	Mn3UV2FPT0WU
NCI-H2029	NVSxWmhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDoU3RKSzVyPUKwMlMzPjZizszN	NEDjXJRUSU6JRWK=
GI-ME-N	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXW5ZVd6UUN3ME2yNE4{Ozd\|IN88US=>	MWPTRW5ITVJ?
OVCAR-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor0TWM2OD1{MD61PFIzKM7:TR?=	NGXjU3ZUSU6JRWK=
HD-MY-Z	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\qTWM2OD1{MT6zOlk3KM7:TR?=	NVuzWmVpW0GQR1XS
NTERA-S-cl-D1	NFTrOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJzLk[3NlIh\|ryP	NGfFUnJUSU6JRWK=
SCH	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInGUotKSzVyPUKyMlQ6PiEQvF2=	Ml\uV2FPT0WU
KARPAS-299	NULGcnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ\|LkO4PFch\|ryP	MXjTRW5ITVJ?
NCI-H1650	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnye4lKSzVyPUKzMlkzPDFizszN	NEm4cnFUSU6JRWK=
ACHN	M33MSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DKVmlEPTB;MkSuOFY2PiEQvF2=	MUTTRW5ITVJ?
M059J	NYTW[3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHzNXFKSzVyPUK0MlU3OzRizszN	NF;rXGJUSU6JRWK=
AM-38	NUTHPYlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fwRWlEPTB;MkWuOFgyKM7:TR?=	NVHjco9UW0GQR1XS
KG-1	M37hN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3DTWM2OD1{NT61OFk1KM7:TR?=	M2XlcnNCVkeHUh?=
COLO-824	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[yPWpTUUN3ME2yOU42PTl7IN88US=>	M1LzRXNCVkeHUh?=
NCI-H1155	M3jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHvTWM2OD1{NT61PFQ4KM7:TR?=	MXfTRW5ITVJ?
NCI-H441	MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M176bWlEPTB;MkWuO\|Q3PSEQvF2=	M4TiTHNCVkeHUh?=
J-RT3-T3-5	NX;NNY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHUTWM2OD1{Nj6zNFI4KM7:TR?=	M1npWXNCVkeHUh?=
JEG-3	M{nMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDoOopkUUN3ME2yOk43QDB3IN88US=>	MYrTRW5ITVJ?
RKO	NF3lflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPoPZR7UUN3ME2yOk44PjN{IN88US=>	M1LZXXNCVkeHUh?=
CAL-85-1	M4Pn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFm4dWlKSzVyPUK3MlIyOThizszN	M{DBcHNCVkeHUh?=
CAL-120	MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTVNnZNUUN3ME2yO{43QTF2IN88US=>	MWLTRW5ITVJ?
NCI-H2452	NX\0NYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrLbJRKSzVyPUK3Mlc4OTZizszN	MVzTRW5ITVJ?
NCI-H1395	NH[ySJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvIepFCUUN3ME2yO{44QDN\|IN88US=>	MoHSV2FPT0WU
KYSE-450	M1Xi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTJTWM2OD1{Nz65PFYzKM7:TR?=	MUfTRW5ITVJ?
S-117	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXoOllKSzVyPUK5MlM5PTdizszN	M4n5XXNCVkeHUh?=
SW13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofQTWM2OD1{OT64OVE6KM7:TR?=	NX\XcZNDW0GQR1XS
ES3	NID0Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX63UoxIUUN3ME2zNE4{PzN\|IN88US=>	NUjVW2hSW0GQR1XS
HCT-116	NF7afXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PTXWlEPTB;M{CuOVU2PCEQvF2=	MWLTRW5ITVJ?
NCI-H1693	NYfhbFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[5UFROUUN3ME2zNE42QTR{IN88US=>	MkLzV2FPT0WU
VM-CUB-1	NV3jc3dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnHPWxKSzVyPUOwMlY1OTNizszN	NES2NXhUSU6JRWK=
NCI-H2170	MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNzLkW3PFQh\|ryP	MnfjV2FPT0WU
ALL-PO	M3LIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjtTWM2OD1\|MT64OFI5KM7:TR?=	MofiV2FPT0WU
NCI-H661	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{P1UGlEPTB;M{KuNFYzOyEQvF2=	NUfNbI0xW0GQR1XS
NCI-H2347	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTN{LkS4N\|ch\|ryP	MWXTRW5ITVJ?
FTC-133	NXGxXXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M330R2lEPTB;M{KuO\|A3KM7:TR?=	M{K1c3NCVkeHUh?=
COLO-829	M{nuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTN\|LkO0Olch\|ryP	NVG4NYlrW0GQR1XS
GOTO	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTN\|LkWyOVgh\|ryP	NIfHeXpUSU6JRWK=
YAPC	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTN\|LkixOVkh\|ryP	MVXTRW5ITVJ?
LCLC-103H	NWrZSHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvW[GZKSzVyPUO0MlE3OjRizszN	NX3lfpBPW0GQR1XS
SiHa	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;ETZNsUUN3ME2zOE4{QDF5IN88US=>	NVXocXJmW0GQR1XS
LK-2	M4f0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjBSZVKSzVyPUO0MlU4ODhizszN	NH2zVoNUSU6JRWK=
KP-N-YS	NFHOOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTN2LkeyNFIh\|ryP	MoLQV2FPT0WU
NCI-SNU-1	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDhUYo4UUN3ME2zOU4yPzlizszN	MofWV2FPT0WU
KNS-81-FD	M2fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XwNmlEPTB;M{WuOlY{KM7:TR?=	M{HM[XNCVkeHUh?=
SCC-9	NHf6cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3m3N2lEPTB;M{[uO\|E1PiEQvF2=	MVfTRW5ITVJ?
SH-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnlPVhKSzVyPUO2Mlc{KM7:TR?=	M1vBeHNCVkeHUh?=
HCC-1954	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfoUYJKSzVyPUO3MlI4OjlizszN	M4qzPHNCVkeHUh?=
BALL-1	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTN5LkWzNVYh\|ryP	NGjnfoZUSU6JRWK=
BE-13	M{DkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzCTYNKSzVyPUO3MlcxOThizszN	NXjZOGpOW0GQR1XS
COLO-678	NF\IS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHe4WJNKSzVyPUO3Mlk1OzdizszN	M1S0UnNCVkeHUh?=
SK-MEL-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLaTWM2OD1\|OD6yN\|k4KM7:TR?=	M4XWO3NCVkeHUh?=
OAW-28	NHvvZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTN6Lk[zPUDPxE1?	MVjTRW5ITVJ?
CAMA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWUppKSzVyPUO4Mlk3QTFizszN	NVTXXm55W0GQR1XS
C2BBe1	NWPLd5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqzT4FKSzVyPUO5MlgyQCEQvF2=	NIfxOoVUSU6JRWK=
A3-KAW	NXTqeYhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnXdVdtUUN3ME20NE4{PjZzIN88US=>	NVnRdlFzW0GQR1XS
SK-MEL-24	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TtUWlEPTB;NECuOVk{OSEQvF2=	MXjTRW5ITVJ?
KYSE-140	M4D4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPEcYNLUUN3ME20NE44OTZ3IN88US=>	NWfYOnBRW0GQR1XS
MOLT-16	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj4PFluUUN3ME20NU4yPTN4IN88US=>	MnnyV2FPT0WU
CFPAC-1	NFXjPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLFTWM2OD12Mj61NlEyKM7:TR?=	M13tN3NCVkeHUh?=
NB14	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTR{LkewNlch\|ryP	NVL5PVRHW0GQR1XS
COLO-792	M322S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTR{Lki5OlEh\|ryP	MWXTRW5ITVJ?
RH-1	NEHQ[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfD[mRTUUN3ME20N{41QDN4IN88US=>	NHXieZNUSU6JRWK=
NCI-H522	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Hq[GlEPTB;NESuN\|U3QCEQvF2=	NXTjWlQ5W0GQR1XS
Ca-Ski	NWjNSpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne4TWM2OD12ND64NVE1KM7:TR?=	Mo\EV2FPT0WU
KGN	M3HxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn1TWM2OD12OD6zNFY{KM7:TR?=	MXXTRW5ITVJ?
UACC-62	M4TzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzQNohKSzVyPUS4MlQxPzJizszN	MlW3V2FPT0WU
NCI-H358	NHK3RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PvR2lEPTB;NEmuN\|AyQCEQvF2=	M2fLZnNCVkeHUh?=
LS-411N	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmG5TWM2OD12OT6zNVE5KM7:TR?=	MX3TRW5ITVJ?
IST-MES1	M4fhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3mVoJKSzVyPUS5MlU3OjVizszN	MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321
Smiles	C[S](=O)(=O)N1CCN(CC1)CC2=CC3=NC(=NC(=C3S2)N4CCOCC4)C5=CC=CC6=C5C=N[NH]6

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)